Gene therapy company Genprex Inc (NASDAQ: GNPX) announced on Monday that its research collaborators from Meharry Medical College will present promising preclinical data on Reqorsa Gene Therapy at the 39th Annual Society for Immunotherapy of Cancer (SITC) meeting from 6-10 November 2024 in Houston, Texas.
The poster, titled 'TUSC2 Modulates Cancer Immune Responses', will highlight Reqorsa's ability to influence immune responses against cancer cells.
Reqorsa, Genprex's lead drug candidate, utilises the TUSC2 tumor suppressor gene delivered through the company's Oncoprex Delivery System, a lipid nanoparticle platform designed to target and deliver TUSC2 to cancer cells while sparing normal tissue. Preclinical studies demonstrated significantly higher TUSC2 uptake in cancer cells compared to normal cells.
Genprex is focused on developing therapies for cancer and diabetes. Reqorsa is currently being tested in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with both programs receiving FDA Fast Track Designation. The SCLC program also holds an FDA Orphan Drug Designation.
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
TME Pharma secures EUR2.4m grant for NOX-A12 Phase 2 trial
Satsuma Pharmaceuticals and Shin Nippon Biomedical resubmit STS101 NDA to FDA
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Sobi to present emapalumab data for treating macrophage activation syndrome at ACR Conference
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant
Johnson & Johnson reports strong Phase 3 results for TREMFYA in Crohn's Disease
Kind Pharmaceutical's AND017 receives US FDA Orphan Drug Designation
RiboX Therapeutics' RXRG001 Phase I/IIa Study IND application receives US FDA approval
Modalis Therapeutics receives Orphan Drug Designation for MDL-101
EpiVax and CUBRC receive USD2m contract from US FDA
U.P. Oncolytics' oncolytic virus-based therapy granted US FDA Orphan Drug designation
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service